Denali signs Lonza to make biologics in first CMO deal

By Flora Southey contact

- Last updated on GMT

GettyImages/digicomphoto
GettyImages/digicomphoto

Related tags: Gene expression, Amyotrophic lateral sclerosis

Lonza has inked a biologics deal with Denali to make neurodegenerative disease therapies, offering the Californian firm opportunity to have production “on their back doorstep.”

The firms announced the partnership – covering all stages of development manufacturing for clinical trials – for diseases such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

Lonza Group will also be responsible for delivering finished drug products for patients, overseen by its in-house Drug Product Services in Basel, Switzerland.

“This is Denali’s first portfolio of drugs, and we will be their first clinical manufacturer,” ​said Lonza's Karen Fallen.

Fallen said the initial development work will be carried out at the contract manufacturing organisation’s (CMO’s) clinical development facility in Slough, UK.

“Denali will then have the option to produce clinical material in both Slough, UK and Hayward, CA, US.

“As Denali are based in California, they have the option of having production ‘on their back doorstep’ if needed,” ​she told us.

The Swiss CMO acquired the Hayward manufacturing facility from Shire in October last year​, to cater for demand for mammalian cell culture-based drug production.

The site added early-phase clinical manufacture on the West Coast, as a complement to Lonza’s Slough facilities, said Fallen.

Denali said the partnership enables access to Lonza’s GS Xceed Gene Expression System, which the CMO claims creates cell lines up to six weeks, encourages improved cell growth, and faster doubling times than its predecessor.

Related news

Show more

Related products

show more

Flexible Filling Solution for CMOs

Flexible Filling Solution for CMOs

Single Use Support GmBH | 18-May-2022 | Insight Guide

Achieving flexibility requires modularity of technologies.

CMOs and CDMOs aspire to be flexible for multiple applications. Efficient automated...

Eastern & Western Manufacturing Solutions

Eastern & Western Manufacturing Solutions

Piramal Pharma Solutions | 15-Mar-2022 | Technical / White Paper

The best manufacturing site for a product can change throughout the life cycle. When bringing new drugs to market, biopharma companies may benefit from...

Related suppliers

Follow us

Products

View more

Webinars